|
|
Article: Critical oncology target licensed from Mass General.
- Article from:
- Biotech Week
- Article date:
- January 29, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 JAN 29 - (NewsRx.com & NewsRx.net) -- Mercury Therapeutics, Inc., (MTI), a privately held biopharmaceutical company, announced that it has recently acquired the exclusive, world-wide rights to a critical drug target in oncology from Massachusetts General Hospital.
The technology will be used by the company to develop small molecule inhibitors to the Ras-Raf protein interaction, a well-validated but completely unexploited oncology drug target.
"We are very pleased to have Mercury Therapeutics license the Ras-Raf technology. They have an excellent group of scientists coupled with a robust high throughput screening capability that will enable them to ...